(Q53853180)

21 May 2018

title

Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. (English)

1 reference

21 May 2018

1 reference

1 reference

12

Wolfgang Schareck

1 reference

21 May 2018

author name string

Jolanta Majcher-Peszynska

1

1 reference

21 May 2018

Marko Sass

2

1 reference

21 May 2018

Sora Schipper

3

1 reference

21 May 2018

Viktor Czaika

4

1 reference

21 May 2018

Andreas Gussmann

5

1 reference

21 May 2018

Ralf Lobmann

6

1 reference

21 May 2018

Ralf G Mundkowski

7

1 reference

21 May 2018

Christoph Luebbert

8

1 reference

21 May 2018

Peter Kujath

9

1 reference

21 May 2018

Bernhard R Ruf

10

1 reference

21 May 2018

Horst Koch

11

1 reference

21 May 2018

Ernst Klar

13

1 reference

21 May 2018

Bernd Drewelow

14

1 reference

21 May 2018

Moxifloxacin-DFI Study Group

15

1 reference

21 May 2018

publication date

25 September 2010

1 reference

21 May 2018

European Journal of Clinical Pharmacology

published in

1 reference

21 May 2018

volume

67

1 reference

21 May 2018

issue

2

1 reference

21 May 2018

page(s)

135-142

1 reference

21 May 2018

https://scigraph.springernature.com/pub.10.1007/s00228-010-0903-5

exact match

0 references

cites work

Diagnosis and treatment of diabetic foot infections

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Tissue and serum levofloxacin concentrations in diabetic foot infection patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

10 years' experience with the pneumococcal quinolone moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Moxifloxacin penetration into human gastrointestinal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Clinical role of protein binding of quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-010-0903-5

Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells

21 January 2018

1 reference

12 December 2020

Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study

1 reference

12 December 2020

Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose

1 reference

12 December 2020

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man

1 reference

12 December 2020

10.1007/S00228-010-0903-5

Identifiers

DOI

1 reference

21 May 2018

PubMed ID

20871984

1 reference

21 May 2018